SCHEMBL17599448

SCHEMBL17599448

Cc1c(S(=O)(=O)Nc2ccc(N3CC[C@@H](C(=O)O)C3)c3ncccc23)c2ccccc2n1C

nearest known ligand 0.73

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KEAP1 Q14145 7/20 0.73
▸ NFE2L2 Q16236 1/20 0.58
▸ ACLY P53396 1/20 0.45
▸ MMP2 P08253 2/20 0.41
▸ SLC40A1 Q9NP59 2/20 0.40
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.38
▸ GAA P10253 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ GFER P55789 1/20 0.38
▸ SMN1; SMN2 Q16637 1/20 0.38
▸ CTSB P07858 2/20 0.38
▸ NOTUM Q6P988 2/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ UQCRB P14927 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17599424 0.89 KEAP1 (0.72) KEAP1NFE2L2ACLYNOTUM
SCHEMBL17599451 0.85 KEAP1 (1.00) KEAP1NFE2L2MMP2SLC40A1TDP1
SCHEMBL17612884 0.85 KEAP1 (1.00) KEAP1NFE2L2MMP2SLC40A1TDP1
SCHEMBL17599418 0.85 KEAP1 (1.00) KEAP1NFE2L2MMP2SLC40A1TDP1
SCHEMBL17599497 0.83 KEAP1 (0.75) KEAP1NFE2L2ACLYMMP2SLC40A1
SCHEMBL17612898 0.82 KEAP1 (0.55) KEAP1NFE2L2ALDH1A1CTSBNOTUM
SCHEMBL17599504 0.81 KEAP1 (0.65) KEAP1NFE2L2MMP2SLC40A1KDM4E
SCHEMBL17599464 0.80 KEAP1 (0.66) KEAP1NFE2L2MMP2SLC40A1TDP1
SCHEMBL17599439 0.80 KEAP1 (0.90) KEAP1NFE2L2MMP2SLC40A1TDP1
SCHEMBL24812743 0.78 KEAP1 (0.87) KEAP1NFE2L2NOTUM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2997966-A1 Naphthyl Sulfonamide Pyrrolidine Derivatives as KEAP-1 Modulators for the Treatment of Diabetes, Obesity, Dyslipidemia and Related Disorders SANOFI (FR) 2016-03-23 — — EP disclosed
Send feedback